Philip Scheltens Selected Research

Institutionalization (Institutionalized Persons)

1/2022	Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment.
1/2020	Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study.
1/2020	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project.
1/2019	Predicting progression in the late onset frontal lobe syndrome.
4/2017	Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the "Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment" (TRACE-VCI) Study.
11/2016	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands.
1/2015	The rest-activity rhythm and physical activity in early-onset dementia.
1/2012	Effectiveness of family meetings for family caregivers on delaying time to nursing home placement of dementia patients: a randomized trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip Scheltens Research Topics

Disease

310	Alzheimer Disease (Alzheimer's Disease) 10/2022 - 08/2002
174	Dementia (Dementias) 10/2022 - 09/2003
156	Cognitive Dysfunction 10/2022 - 03/2002
82	Atrophy 01/2022 - 03/2002
23	Disease Progression 01/2022 - 06/2012
18	Frontotemporal Dementia (Semantic Dementia) 01/2020 - 09/2003
11	Amyloid Plaque 01/2021 - 01/2011
9	Inflammation (Inflammations) 01/2022 - 08/2002
8	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2020 - 09/2003
8	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/2018 - 01/2003
5	Amyloidosis 06/2022 - 03/2013
5	Genetic Risk Score 01/2021 - 01/2016
5	Parkinson Disease (Parkinson's Disease) 01/2021 - 01/2015
5	Hypertension (High Blood Pressure) 01/2010 - 07/2004
4	Memory Disorders (Memory Loss) 01/2021 - 01/2006
4	Pathologic Processes 10/2020 - 12/2004
4	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2019 - 11/2009
4	Infarction (Infarctions) 01/2019 - 01/2007
3	Ovarian Neoplasms (Ovarian Cancer) 06/2021 - 01/2018
3	Breast Neoplasms (Breast Cancer) 06/2021 - 01/2018
3	Multiple Sclerosis 06/2021 - 01/2017
3	Tauopathies 01/2021 - 09/2003
3	Edema (Dropsy) 01/2018 - 07/2011
3	Neurobehavioral Manifestations 01/2018 - 12/2011
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 12/2017 - 01/2006
3	Cerebral Small Vessel Diseases 01/2015 - 10/2012
2	Infections 01/2022 - 04/2010
2	Myocardial Infarction 06/2021 - 01/2019
2	Sepsis (Septicemia) 06/2021 - 01/2019
2	Malnutrition (Nutritional Deficiencies) 01/2020 - 05/2019
2	Primary Progressive Aphasia 01/2020 - 11/2018
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 11/2009
2	Vascular Diseases (Vascular Disease) 01/2020 - 01/2006
2	Neoplasms (Cancer) 01/2019 - 01/2018
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2019 - 12/2015
2	Cerebrovascular Trauma 01/2019 - 01/2019
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 12/2018 - 11/2013
2	Neuroinflammatory Diseases 05/2018 - 01/2016
2	Synucleinopathies 01/2018 - 01/2010
2	Lewy Body Disease (Lewy Body Dementia) 08/2017 - 07/2013
2	Corticobasal Degeneration 08/2017 - 01/2016

Drug/Important Bio-Agent (IBA)

196	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2003
157	Amyloid (Amyloid Fibrils)IBA 10/2022 - 01/2006
59	Apolipoproteins E (ApoE)IBA 01/2022 - 03/2002
36	Pemetrexed (MTA)FDA Link 01/2020 - 07/2004
28	Amyloid beta-PeptidesIBA 12/2021 - 07/2005
26	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2006
24	ApolipoproteinsIBA 01/2022 - 03/2002
16	Biological ProductsIBA 10/2022 - 01/2002
13	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2006
11	Pharmaceutical PreparationsIBA 11/2021 - 05/2011
11	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2021 - 12/2017
9	Threonine (L-Threonine)FDA Link 01/2022 - 01/2010
9	Peptides (Polypeptides)IBA 06/2021 - 09/2013
8	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2019 - 08/2010
6	Cholinergic Agents (Cholinergics)IBA 01/2022 - 12/2004
6	Blood Proteins (Serum Proteins)IBA 01/2021 - 01/2018
6	EnzymesIBA 01/2020 - 11/2009
5	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2022 - 01/2006
5	NeurograninIBA 10/2021 - 10/2015
4	Galantamine (Galanthamine)FDA LinkGeneric 01/2022 - 01/2006
4	flutemetamolIBA 01/2022 - 01/2017
4	Memantine (Namenda)FDA Link 10/2021 - 01/2004
4	DNA (Deoxyribonucleic Acid)IBA 10/2021 - 01/2014
4	Phosphotransferases (Kinase)IBA 01/2021 - 07/2014
4	HomocysteineIBA 10/2020 - 06/2007
4	Retinaldehyde (Retinal)IBA 12/2019 - 01/2018
4	ImmunosorbentsIBA 01/2019 - 11/2009
4	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 10/2012 - 01/2012
3	IceIBA 06/2021 - 01/2018
3	florbetapirIBA 01/2021 - 01/2019
3	HDL LipoproteinsIBA 01/2021 - 05/2008
3	Folic Acid (Vitamin M)FDA LinkGeneric 10/2020 - 01/2015
3	IronIBA 10/2020 - 12/2007
3	UridineIBA 01/2020 - 01/2015
3	Antihypertensive Agents (Antihypertensives)IBA 01/2015 - 01/2006
3	PK 11195 (PK11195)IBA 01/2013 - 09/2007
3	Verapamil (Calan)FDA LinkGeneric 10/2012 - 01/2012
3	2- (1- (6- ((2- fluoroethyl)(methyl)amino)- 2- naphthyl)ethylidene)malononitrileIBA 06/2012 - 02/2009
2	Glial Fibrillary Acidic ProteinIBA 01/2022 - 01/2020
2	Indicators and Reagents (Reagents)IBA 10/2021 - 07/2013
2	Chitinase-3-Like Protein 1IBA 10/2021 - 09/2015
2	VitaminsIBA 10/2020 - 01/2015
2	Triglycerides (Triacylglycerol)IBA 10/2020 - 05/2008
2	LipidsIBA 10/2020 - 01/2014
2	Complement System Proteins (Complement)IBA 01/2020 - 01/2019
2	4- (N- methylamino)- 4'- (2- (2- (2- fluoroethoxy)ethoxy)ethoxy)stilbeneIBA 10/2019 - 01/2018
2	PhosphopeptidesIBA 01/2019 - 01/2018
2	glutaminyl-peptide cyclotransferaseIBA 10/2018 - 06/2017
2	gantenerumabIBA 01/2018 - 12/2017
2	Monoclonal AntibodiesIBA 01/2018 - 01/2013
2	bapineuzumabIBA 01/2018 - 05/2016
2	pleiotrophin (HARP)IBA 10/2017 - 02/2015
2	Phospholipids (Phosphatides)FDA LinkGeneric 01/2017 - 01/2014

Therapy/Procedure

14	Activities of Daily Living (ADL) 01/2021 - 01/2010
12	Therapeutics 01/2021 - 07/2004
8	Institutionalization (Institutionalized Persons) 01/2022 - 01/2012
7	Secondary Prevention 10/2020 - 04/2006
3	Home Nursing (Nursing, Home) 05/2015 - 01/2005
2	Precision Medicine 11/2019 - 12/2018